腎臓病に関する - pharm.kumamoto-u.ac.jp

1 2015 5 Ccr Cockcroft and Gault GFR eGFR eGFR mL/min Cr CCr C 1 2 eGFR mL/ CKD eGFR mL/min 3 Cockcroft-Gault CCr CCr 4 Cr C eGFR eGFR(mL/ ) GFR eGFR mL/ CKD CKD eGFR mL/min CKD GFR CKD 190cm 110kg 30 Cr A 145cm 39kg 30 Cr B A eGFR eGFR B eGFR eGFR B eGFR 60mL/min<GFR B 30 CKD ( 2)

2 B 60mL/min CKD eGFR mL/ eGFR mL/min C C C C Cr protein energy wasting (PEW) Cr Cr Cr C Cr C ERM-DA471/IFCC) C C eGFR Cr eGFR C Cr eGFRcys C 3 1 Cr eGFR GFR cys (mL/ )

3 = 104 if female 8 eGFRcys=eGFRcys ADL TDM Cr Cr CCr GFR C eGFR 3 1 ADL Cr eGFR eGFR GFR Cockcroft CCr CCr GFR CCr Cr Calvert AUC/CL CL AUC CL AUC 7 7.

4 =CLtotal AUC Calvert mg AUC mg/mL min [GFR mL/min +25] 300 400mg/m2 80 GFR100mL/min+ CL25mL/min=125mL/min GFR + AUC AUC GFR Calvert GFR 51Cr-EDTA GFR AUC(min mg/L) CCr CCr= mL/min 1 Cr mg/mL / Cr mg/dL CCr GFR GFR GFR= mL/min mg/mL / mg/dL Cr CCr GFR Calvert GFR CCr GFR CCr GFR GFR Jaffe CCr Jaffe Cr CCr 20~30 Jaffe CCr GFR Calvert GFR CCr CCr GFR Cr 1990 Cr 20~30 Jaffe CCr Calvert Jaffe IDMS isotope dilution mass spectrometry Cr NIH.

5 National Institutes of Health 2010 10 8 , 2015 5 26 GFR 125mL/min CL 150mL/min AUC Cr GFR 150mL/min 150mL/min AUC GFR Cr CCr Cr CCr Cockcroft-Gault eCCr= kg [140 ] /[72 Cr mg/dL ] mL/ Cockcroft-Gault CCr GFR GFR Cr Cr Cockcroft-Gault eGFR CCr CCr Cockcroft eGFR mL/min CCr Cr Jaffe CCr GFR eGFR mL/ CCr mL/ )

6 EGFR mL/min CCr mL/min CCr GFR SGLT2 L- eGFR mL/ eGFR mg/ mL/ mg/kg, mg/m2 mL/ mL/min Cr Jaffe Cr 20 30 CCr Cr Jaffe GFR IDMS isotope dilution mass spectrometry Cr NIH: National Institutes of Health eGFR CCr Jaffe GFR CCr GFR GFR CCr Cockcroft Cockcroft eGFR CCr mL/min eGFR mL/ CG Cr GFR CCr CG 1 1mL/min GFR CG eGFR mL/ )

7 CG Cr eGFR mL/min CG CG HP CKD HP HP 200 1400 2 1 2015 12 CKD NG CKD HP 40 ( 10 50mL/ 12 24 2g 12 24 1 2 7 14 12 24 time above MIC 100 10 50mL/ RIFLE criteria AKIN criteria AKI (24hrCcr ))

8 RIFLE criteria AKIN criteria KDIGO AKI AKI Cr GFR AKI eGFR Cr Cr Cr AKI CCr AKI NGAL AKI NAG, MG, 1MG L-FABP, NGAL, KIM-1 AKI NAG, MG, 1MG AKI Cystatin C ST ST GFR CCr 30 C eGFR GFR ST CCr GFR CCr CKD stage G4 GFR 30mL/ stage G3 30 GFR 60mL/ stage G2 60 GFR 90mL/ 15mL/ GFR stage G5 CCr 30mL/min 30 CCr 60mL/min

9 60 CCr 90mL/min CKD GFR CCr CCr GFR Cr Cr Jaffe Cr Cr 20 30 CCr CCr mL/min = Cr mg/dL L/ / Cr mg/dL 80mg/dL mg/dL =120mL/min Jaffe Cr CCr=GFR Cr / / Cr Jaffe CCr GFR 80mg/dL / + mg/dL/dL=100mL/min GFR CCr GFR GFR CCr 100mL/min 120 130 mL/min 10mL/min GFR CCr 15mL/min GFR CCr 1 ( )

10 PubMed Abstract 1 80 C 2015 10 17 18 VCM TDM VCM VCM TDM VCM BUN/Cr BUN/Cr 10 20 VCM VCM Na FENa 1 VCM VCM FENa AKI VCM VCM TDM VCM 1~2 3~6kg BUN/Cr FENa FENa FEurea Na (FENa,% mOsm/kgH2O) Na mEq/L) Cr/ C (FEurea,% BUN/Cr 1 500 20 40 35 10 2 350 40 20 50 20 HbA1c ( )